natgillin/translations-raw huggingface dataset:
A minor infection such as a cold should not be a problem, but your doctor or nurse should advise whether you could still be vaccinated with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, 
Blaţja okuţba kot je prehlad ne predstavlja teţave, vendar vam bosta zdravnik ali medicinska sestra svetovala, ali se lahko še vedno cepite s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics,
Pain, hardening of the skin at the injection site, injection site redness, injection site swelling, pain at the site of injection, aching muscles, headache, sweating, fatigue. 
Bolečina, otrdelost koţe na mestu injiciranja, pordečeno in oteklo mesto injiciranja, bolečina na mestu injiciranja, bolečine v mišicah, glavobol, zvečano potenje, utrujenost
Fever ≥ 38°C (≥ 40°C) Any Other Adverse Event 
vsi lokalni sistemski zvišana telesna temperature ≥ 38 °C (≥ 40 °C) vsi drugi neţeleni učinki
A clinical trial (Study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant in 471 children from 6 months to 17 years of age. 
Opravili so klinično preskušanje (študija V87P6) za kombinacijo cepiva H5N1 in adjuvansa MF59C.1 pri 471 otrocih, starih od 6 mesecev do 17 let.
Since a second dose is recommended, it should be noted that there are no safety, immunogenicity or efficacy data to support interchangeability of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics with other H5N1 monovalent vaccines. 
Ker je priporočljivo cepljenje z drugim odmerkom, je treba opozoriti, da ni podatkov o varnosti, imunogenosti ali učinkovitosti, ki podpirajo zamenljivost cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics z drugimi monovalentnimi cepivi H5N1.
Immunization shall be postponed in patients with febrile illness or acute infection. 
Imunizacijo pri bolnikih s povišano telesno temperaturo ali akutno okuţbo je treba preloţiti.
Some cross-protection was observed against related H5N1 virus variants in clinical trials (see section 
V kliničnih preskušanjih so opazili določeno stopnjo navzkriţne zaščite proti različicam virusa H5N1 (glejte poglavje 5.1).
MN results against a A/Vietnam/1194/2004 indicate a seroprotection rate of 99% (95%CI: 94-100), a seroconversion rate ranging from 97% (95%CI: 91-99) to 99% (95%CI: 96-100) and a GMR ranging from 29 (95%CI: 25-35) to 50 (95%CI: 44-58). 
Rezultati MN za sev A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite 99 % (95-odstotni IZ: 94100), stopnjo serokonverzije v razponu od 97 % (95-odstotni IZ: 91-99) do 99% (95-odstotni IZ: 96100) in GMR v razponu od 29 (95-odstotni IZ: 25-35) do 50 (95-odstotni IZ: 44-58).
* measured by SRH assay ≥ 25 mm2 ** geometric mean ratios of SRH 
* izmerjeno s testom SRH ≥ 25 mm ** razmerja geometričnih srednjih vrednosti za SRH
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients and to residues (eggs and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)). 
Previdnost je potrebna pri cepljenju oseb z znano preobčutljivostjo (poleg anafilaktične reakcije) na zdravilno učinkovino, katerokoli pomoţno snov ali snov v sledovi (jajčne ali piščančje beljakovine, ovalbumin, kanamicinsulfat in neomicinsulfat, formaldehid in cetiltrimetilamonijev bromid (CTAB)).
Generalised skin reactions including itching, urticaria (hives), rash or swelling of the skin and mucous membranes. 
Generalizirana koţna reakcija vključno s srbenjem, urtikarijo (koprivico), izpuščajem ali oteklino koţe in sluznice.
The incidence of adverse reactions has been evaluated in six clinical trials involving approximately 4,000 adults and elderly receiving (Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics at least 7.5 µg HA, adjuvanted). 
Pogostnost neţelenih učinkov so ocenili v šestih kliničnih preskušanjih, ki je zajela pribliţno 4.000 odrasnih in starejših oseb, ki so prejele cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (vsaj 7,5 µg HA, z adjuvansom).
Very limited data in subjects with co-morbidities, including immunocompromised subjects are available for this H5N1 vaccine. 
Za to cepivo H5N1 so na voljo zelo omejeni podatki za osebe s sočasnimi boleznimi, vključno z osebe z oslabljenim imunskim sistemom.
In another clinical trial (Study V87P13) 2693 adult subjects were enrolled and received two doses of vaccine containing H5N1 (A/Vietnam/1194/2004; 7.5 µg HA/dose adjuvanted) administered three weeks apart. 
V drugem kliničnem preskušanju (študija V87P13) so vključili 2.693 odraslih, ki je v 3-tedenskem presledku prejelo dva odmerka cepiva, ki vsebuje H5N1 (A/Vietnam/1194/2004; 7,5 µg HA/odmerek z adjuvansom).
Generalised skin reactions including pruritus, urticaria or non-specific rash; angioedema. 
Bolezni koţe in podkoţja generalizirane koţne reakcije vključno s pruritusom, urtikarijo ali nespecifičnim izpuščajem; Angioedem
Name and address of the manufacturers of the biological active substance Novartis Vaccines and Diagnostics S.r.l. 
Ime in naslov izdelovalcev biološke zdravilne učinkovine Novartis Vaccines and Diagnostics S.r.l.
Efficacy against challenge with virus homologous and heterologous to vaccine strains was evaluated in the ferret model. 
Sposobnost za indukcijo zaščite proti homolognim in heterolognim cepilnim sevom so ocenili predklinično s provokacijskim modelom pri belem dihurju.
Fever ≥ 38°C (≥ 40°C) Any Other Adverse Event Children (3-<9 years) 
vsi lokalni sistemski zvišana telesna temperature ≥ 38 °C (≥ 40 °C) vsi drugi neţeleni učinki Otroci (3-<9 let)
In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics that contained HA antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics instead of two doses that are required in previously unvaccinated individuals (see section 5.1). 
V primeru uradne objave pandemije gripe zaradi virusa A/H5N1 se lahko osebam, predhodno cepljenim z enim ali dvema odmerkoma cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, ki vsebuje antigen HA, izpeljan iz drugačne gruče enakega podtipa gripe kot pandemski sev gripe, lahko prejmejo en odmerek cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics namesto dveh, ki sta potrebna za predhodno necepljene osebe (glejte poglavje 5.1).
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in subjects aged over 60 (limited number of subjects were above 70 years of age) measured by SRH assay assessed in two clinical studies were as follows: 
Stopnja serozaščite*, deleţ serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004 pri osebah, starih več kot 60 let (omejeno število oseb je bilo starih nad 70 let), izmerjeno s testom SRH, ocenjeno v dveh kliničnih preskušanjih, so bili kot sledi:
Fever ≥ 38°C (≥ 40°C) Any Other Adverse Event Adolescents(9-<18 years) 
vsi lokalni sistemski zvišana telesna temperature ≥ 38 °C (≥ 40 °C) vsi drugi neţeleni učinki Mladostniki (9-<18 let)
Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate Sodium citrate 
natrijev klorid kalijev klorid kalijev dihidrogenfosfat dinatrijev hidrogenfosfat magnezijev klorid heksahidrat kalcijev klorid dihidrat natrijev citrat citronska kislina voda za injekcije
Lymphadenopathy. 
Bolezni ţivčevja
c) 
IZ)**
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: 
V razvrstitvah pogostosti so neţeleni učinki navedeni po padajoči resnosti: Bolezni ţivčevja
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)) of this vaccine. 
Anafilaktične (tj. ţivljenjsko nevarne) reakcije v anamnezi na katerokoli sestavino cepiva ali ostanke v sledeh (jajčne in kokošje beljakovine, ovalbumin, kanamicinsulfat in neomicinsulfat, formaldehid in cetiltrimetilamonijev bromide (CTAB)) v cepivu.
The safety and efficacy of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in subjects under 18 years of age have not yet been established. 
Varnost in učinkovitost cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics pri preiskovancih, starih do 18 let, še nista bili dokazani.
It is estimated that more than 90,000 women have been vaccinated during pregnancy with H1N1v vaccine Focetria which contains the same amount of adjuvant MF59C.1 as. Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics However information on outcomes is currently limited. 
Ocenjuje se, da je bilo med nosečnostjo cepljenih več kot 90.000 ţensk s cepivom Focetria (H1N1v), ki vsebuje enako količino adjuvansa MF59C.1 kot cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** 
Stopnja serozaščite (95-odstotni IZ)* Stopnja serokonverzije (95-odstotni IZ)* Faktor serokonverzije (95-odstotni IZ)**
All (100%) animals receiving 2 doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected, and 94% of animals receiving a single dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics were protected. 
Zaščitene so bile vse ţivali (100 %), ki so prejele 2 odmerka cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in 94 % ţivali, ki so prejele en odmerek cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively. 
Rezultati MN za A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite v razponu od 67 % (60-74) do 85 % (78-90) in stopnjo serokonverzije v razponu od 65 % (58-72) do 83 % (77-89).
Data obtained in adults showed that co-administration of adjuvanted H5N1 vaccine and seasonal (inactivated surface, non-adjuvanted) antigens did not lead to any interference neither for seasonal strains nor for H5N1 strains. 
Podatki, pridobljeni pri odraslih, kaţejo, da sočasno dajanje cepiva H5N1 z adjuvansom in sezonskih (površinsko inaktiviran, brez adjuvansa) antigenov ne povzroči medsebojnega delovanja niti za sezonske seve, niti za seve H5N1.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old). 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je cepivo, ki se uporablja pri odraslih (starih med 18 do 60 let) in starejših osebah (starih nad 60 let).
The European Medicines Agency has deferred the obligation to submit the results of studies with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) in one or more subsets of the paediatric population in active immunisation against H5N1 subtype of Influenza A virus. 
Evropska agencija za zdravila je začasno odloţila obvezo za predloţitev rezultatov študij s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) za eno ali več podskupin pediatrične populacije za aktivno imunizacijo proti podtipu H5N1 virusa influence A. Za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2.
A single vaccination with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) induced high and rapid serological response in subjects primed 6-8 years previously with two doses of a different surrogate H5N vaccine, having same formulation as Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics but using the strain H5N3. 
Eno cepljenjem s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) je povzročilo visok in hiter serološki odziv pri osebah, ki so bile 6-8 let pred tem primarno imunizirane z dvema odmerkoma različnih nadomestnih cepiv za H5N, z enako formulacijo kot cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, a s sevom H5N3.
The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use from 6 months of age and with a composition that is similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics): 
O naslednjih neţelenih učinkih so poročali iz spremljanja v obdobju trţenja s cepivom Focetria H1N1v (odobreno za uporabo pri starosti več kot 6 mesecev, pri čemer je sestava podobna sestavi cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics):
MN results against A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively. 
Rezultati MN za A/Vietnam/1194/2004 kaţejo na stopnjo serozaščite v razponu od 57 % (50-64) do 79 % (68-87) in stopnjo serokonverzije v razponu od 55 % (48-62) do 58 % (47-69).
Common: Brusing of the skin at the injection site, fever and nausea, generally feeling unwell and shivering. 
Pogosti: Modrice na koţi na mestu injiciranja, zvišana telesna temperature, splošno slabo počutje in tresenje
Co-administration was not associated with higher rates of local or systemic reactions compared to administration of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics alone. 
Sočasne uporabe ni spremljal večji deleţ lokalnih ali sistemskih reakcij v primerjavi z uporabo cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics samega.
Non-clinical data obtained with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics and with seasonal influenza vaccine containing MF59C.1 adjuvant reveal no special hazard for humans based on conventional studies of repeated dose toxicity, local tolerance, female fertility, and reproductive and developmental toxicity (through the end of the lactation period). 
Predklinični podatki za cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics in sezonsko cepivo proti gripi, ki je vsebovalo adjuvans MF59C.1, na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih, lokalnega prenašanja, plodnosti pri ţenskah in vpliva na sposobnost razmnoţevanja in razvoja (do konca obdobja dojenja) ne kaţejo posebnega tveganja za človeka.
In a phase 2 clinical trial (Study V87P3) adult subjects aged 18-65 years primed 6-8 years previously with 2 doses of MF59-adjuvanted H5N3 vaccine /A/Duck/Singapore/97 were administered 2 booster doses of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics SRH results after the first dose, that mimic prepandemic priming plus single heterologous booster dose, met all CHMP criteria. 
V 2. fazi kliničnega preskušanja (študija V87P3) so odrasli, stari od 18 do 65 let, ki so 6-8 let pred tem prejeli 2 primarna odmerka cepiva H5N3 virusa /A/Duck/Singapore/97 z adjuvansom MF59, prejeli 2 obnovitvena odmerka cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics should be used in accordance with official recommendations. 
Cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je treba uporabljati v skladu z uradnimi priporočili.
CONDITIONS OF THE MARKETING AUTHORISATION 
ŠTEVILKA DOVOLJENJA ZA PROMET
As with all vaccines, Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may not fully protect all persons who are vaccinated. 
Kot druga cepiva morda tudi zdravilo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics ne bo popolnoma zaščitilo vseh cepljenih oseb.
Tell your doctor if you are breast-feeding and follow his advice. 
Če dojite, to povejte svojemu zdravniku in upoštevajte njegova navodila.
% SP (95% CI) Day 43 
% SZ (95-odstotni IZ)
Gently shake before use. 
Pred uporabo neţno pretresite.
Posology: 
Serija:
The magnitude of immune response was lower in the group who received the 2 
Moč imunskega odziva je bila niţja v skupini, ki je prejela 2. odmerek 1 teden kasneje in višja v skupini z daljšimi reţimi presledkov.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics containing HA from A/Vietnam/1194/2004 (homologous to the challenge strain) and an Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics -like H5N1 vaccine, containing hemagglutinin from the A/turkey/Turkey/1/2005-like (heterologous to the challenge strain) were tested. 
Preskušali so cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, ki je vsebovalo HA seva A/Vietnam/1194/2004 (homologni na provokacijski sev) in cepivo H5N1, podobno cepivu Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, ki je vsebovalo hemaglutinin iz seva A/turkey/Turkey/1/2005 podobnega sevu (heterologni na provokacijski cev).
Any 
O
The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and an MF59 seasonal adjuvanted trivalent vaccine with a composition similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (surface antigen, inactivated, adjuvanted with MF59C.1) that is licensed for use in elderly subjects 65 years of age and older: Blood and lymphatic system disorders 
Iz spremljanja v obdobju trţenja so poročali o naslednjih neţelenih učinkih s sezonskimi trivalentnimi cepivi brez adjuvansov v vseh starostnih skupinah in pri sezonskem trivalentnem cepivu MF59 z adjuvansom s podobno sestavo kot jo ima cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (s površinskimi antigeni, inaktivirano, z adjuvansom MF59C.1), ki je odobren za uporabo pri osebah, starih več kot 65 let:
Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) 
Sev* virusa influence s površinskimi antigeni (hemaglutinin in nevraminidaza): sevu A/Vietnam/1194/2004 (H5N1) podoben sev (NIBRG-14) 7,5 mikrogramov** na 0,5 ml odmerek
A third (booster) dose of Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics was administered 6 months onwards after the primary vaccination. 
Tretji (obnovitveni) odmerek cepiva Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je bil dan po 6 ali več mesecih po primarnem cepljenju.
* propagated in eggs ** expressed in microgram haemagglutinin. 
* razmnoţen v jajcih ** izraţeno v mikrogramih hemaglutinina Adjuvans MF59C.1 vsebuje: skvalen
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 measured by SRH assays were as follows: 
Stopnja serozaščite*, deleţ serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004, izmerjeno s testi SRH, so bili kot sledi:
PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. 
suspenzija za injiciranje v napolnjeni injekcijski brizgi mlečno-bela tekočina
This section describes the clinical experience with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics following a two-dose administration and booster. 
To poglavje opisuje klinične izkušnje s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics po dajanju dveh odmerkov in obnovitvenega odmerka.
The seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 in the adults measured by SRH assay was as follows: 
Stopnja serozaščite*, deleţ serokonverzije* in faktor serokonverzije** za protitelo proti HA na H5N1 A/Vietnam/1194/2004 pri odraslih, izmerjeno s testom SRH, so bili kot sledi:
Intramuscular use 
NAVODILO ZA UPORABO
Read all of this leaflet carefully before you start receive this vaccine. 
Preden se cepite, natančno preberite navodilo!
Data obtained in adults showed that Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics can be given at the same time as nonadjuvanted seasonal influenza vaccines, with injections made into separate limbs. 
Podatki, pridobljeni pri odraslih, kaţejo, da se lahko cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics daje sočasno s sezonskimi cepivi proti gripi, ki ne vsebujejo adjuvansa, pri čemer se cepivi dajeta vsaka v svojo okončino.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspension for injection in pre-filled syringe Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) 
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics suspenzija za injiciranje v napolnjeni injekcijski brizgi prepandemsko cepivo proti gripi (H5N1) (s površinskimi antigeni, inaktivirano, z adjuvansom)
Limited data was obtained from women who became pregnant during the course of clinical trials with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics or H1N1v vaccines adjuvanted with MF59C.1. 
Obstajajo omejeni podatki pri ţenskah, ki so v teku kliničnih preskušanj s cepivoma Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1) ali H1N1v z adjuvansom MF59C.1 zanosile.